Minutes meeting Scandiatransplant 2023-12-05.

On-line, TEAMS

Present: Susanne, Søren, Ingvild, Ilkka, Ilse, Magnus, Bryndis, Gisela, Morten, Helena, Ola (last part)

- 1. Presentation of new members: Ilse Duus Weinreich DK Scandiatrspl, Søren Jensen-Fangel DK, Bryndis Sigurðardóttir Iceland.
- 2. Survey of the laboratory capacity regarding analyses for Infection screening of deceased donors throughout the Scandiatransplant centres. Ilse presents the results.

The results of the survey will be used in the continuing work with revision of the guidelines. The survey will also function as a standard for the types of analyses that laboratories serving transplant centres should provide.

3. Covid19. The group agrees upon that the guidelines regarding Covid in deceased donors are still up to date with no need for changes at this point.

The matter of testing asymptomatic recipients for SARSCoV2 preoperatively was discussed. This is done differently throughout the centres. In the countries where asymptomatic recipients are tested, transplantations are often deferred which is problematic.

Discussion regarding the possibility to give recommendations on this topic. Difficult due to lack of evidence in the literature. The group decided to collect data from the participating centres regarding Covid-positive recipients during the last months and their outcome.

Ingvild, Morten, Sören & Gisela will take responsibility for this project.

4. Influenza in the donor. Bryndis made a presentation.

1-2% of donors may have active influenza during flu season. Many centres have screening-analyses that include not only SARS-CoV-2 but also influenza and RSV. More questions regarding Influenza (and RSV) will probably come up.

The group agreed upon including a section on Influenza in donors in the guidelines. State a time frame for how long after Influenza lungs may be used, if evidence is found.

Bryndis, Susanne & Ilkka will write a suggestion for this section of the guideline.

5. Accessibility of information from the ID-group.

Discussion regarding changing the layout of the guideline and/or the possibility of having an electronic version that could be updated at regular basis? Changes in the guideline need to be approved by the Council.

Possible to construct a separate headline for the ID-group on the Scandiatrspl website? **Ilse** will investigate this.

Possible to include the Infection guideline into the YASWA system? This would give the document more impact.

Discussions to be continued in the next meeting.

6. CMV prevention. Information regarding CMV-prophylaxis in Sweden and Norway was presented. There are wide differences in the routines for prophylaxis.

Different CMV-prophylaxis strategies and risk for CMV-infection/reactivation: topic for further research project.

The group decided to start by gathering information regarding routines for CMV-prophylaxis from all centres. Susanne will collect information for Denmark. Ilkka will collect for Finland and will also reach out to the Estonian representative.

Ola will take responsibility for this project, together with Ingvild, Susanne and Ilkka.

7. VZV-vaccination. Differences regarding recommendation for Shingrix were discussed. Shingrix is given to IgG-positives in Denmark, Finland, Norway and in some centres in Sweden (in Norway also given as primary immunization for IgG-negative recipients).

Problems in many centres (Sweden, Iceland) due to the high cost of the vaccine and a lack of finance agreement from the health care institutions. Recipients should not have to pay for the vaccine themselves.

Not very clear evidence of efficacy in the SOT-population. A large study on kidney-trspl is ongoing. Results not yet available. Lack of cost-benefit data.

8. Other topics.

Ingvild: prophylaxis before pancreas trspl. How do we do it? Is there a need to look into the routines? Collect information from all centres. Last year 49 st pancreas transplantations within Scandiatrspl. Next meeting?

Magnus: RSV-vaccine? Limited evidence to recommend vaccination. The group decided to collect data on respiratory viruses in transplant recipients. **Ola and Magnus**

The group needs a secretary, so far we have used ad hoc appointment of a member. **Susanne** was granted the opportunity to try to recruit a PhD student from her site.

- 9. Prospects for future research collaboration
 - CMV (see above)
 - Covid as well as RSV and Influenza (see above). One or two separate projects?

The group can apply for funding from Scandiatransplant. Deadline February 1st 2024. **Ola?**

10. Next meeting. On-site. Copenhaguen. April 11th 2024.

The participants will be contacted by Scandiatransplant regarding the travel arrangements.

/Helena Hammarström 231206